天士力(600535.SH):與Takara Bio終止有關C-REV的相關合作
格隆匯 8 月 4日丨天士力(600535.SH)披露控股子公司引進Takara Bio Inc.公司產品的進展,經公司控股子公司天士力生物醫藥股份有限公司(“天士力生物”)與Takara Bio Inc.公司(日本寶生物工程株式會社,“Takara”)協商一致,決定終止有關治療胰腺癌及黑色素瘤的溶瘤病毒產品(“C-REV”)的相關合作並於日前簽署了終止協議。原許可協議由天士力生物於2020年5月11日與Takara達成,根據協議約定,天士力生物擁有在中國(包括中國大陸、香港及澳門,不包括台灣,“合作區域”)排他性的開發、註冊、生產和商業化的權益。
因受全球新冠疫情進展影響,Takara和天士力生物C-REV項目技術轉移被顯著拖延,進而影響該項目在合作區域的開發進度,經雙方友好協商,一致同意終止有關C-REV的相關合作。截至公告披露日,就該項目天士力生物尚未發生任何款項的支付,未在國內開展臨牀前研究,未發生研發投入。
終止合作後,相關機密信息和原始文件將銷燬或返還,雙方無其他任何款項糾紛。此次與Takara公司終止合作後,天士力生物不再擁有C-REV產品在合作區域的開發、註冊、生產和商業化權益,不會對公司財務狀況及經營成果構成重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.